CollaGenex Pharmaceuticals is Awarded $962,000 NIH Grant to Support Research of Potent Anti-Inflammatory Effects of Incyclinide

14-Nov-2005

CollaGenex Pharmaceuticals, Inc. announced that the National Institutes of Health ("NIH") has awarded a grant of approximately $962,000 for additional research into the potent anti-inflammatory effects of incyclinide (formerly known as Col-3), the Company's compound currently in Phase II clinical trials for the treatment of acne.

The grant will be paid over two years and will support CollaGenex's manufacturing and formulation development of incyclinide as well as preclinical studies by Gary Nieman, a research collaborator from the State University of New York, and Jay Zwischenberger, M.D., a research collaborator from the University of Texas, Galveston. Gary Nieman conducted earlier studies with incyclinide in models for acute inflammation, and he and Dr. Zwischenberger will conduct additional studies that should advance the Company's understanding of incyclinide's potent anti-inflammatory properties.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance